Acquisition Pending

Eli Lilly acquisition of Curevo Vaccine

US$1.5bn consideration

Announced 26 May 2026

Advisers

Target
Curevo Vaccine
Acquirer
Eli Lilly
Target based in
United States (unverified)
Buyer based in
United States
Sector
Biotech
Tags
Biotech, Drug Development

In the league tables

Similar deals

All biotech deals →

Sources

Suggest a correction

A missing adviser, a wrong role or a different outcome. A link to a public source helps.